{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:39:38Z","timestamp":1770975578908,"version":"3.50.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/ftd.0b013e318274197e","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T09:13:05Z","timestamp":1353489185000},"page":"78-83","source":"Crossref","is-referenced-by-count":36,"title":["Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor"],"prefix":"10.1097","volume":"35","author":[{"given":"Claudia P.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammara","family":"Chaikan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J. L. la","family":"Porte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":". Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":". Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/00003088-200544080-00006","article-title":". Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.","volume":"44","author":"Kappelhoff","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/QAD.0b013e32830163ad","article-title":"Clinical impact of patient population differences and genomic variation in efavirenz therapy.","volume":"22","author":"King","year":"2008","journal-title":"AIDS"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":". Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.","volume":"13","author":"Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":". In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":". Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.","volume":"320","author":"Faucette","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 6","key":"R8-8-20210129","first-page":"10","article-title":"The pharmacogenetics of response to antiretroviral therapy.","volume":"26","author":"Rodriguez-Novoa","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.pharmtox.48.113006.094753","article-title":"Pharmacogenetics of anti-HIV drugs.","volume":"48","author":"Telenti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":". Impact of CYP2B6 983TC polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":". Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":". CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.2008.271","article-title":". Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.","volume":"85","author":"Arab-Alameddine","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0090-9556(24)14935-5","article-title":". Identification and characterization of efavirenz metabolites by liquid chromatographymass spectrometry and high field NMR: species differences in the metabolism of efavirenz.","volume":"27","author":"Mutlib","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/14622416.9.1.71","article-title":"Pharmacogenetics of the constitutive androstane receptor.","volume":"9","author":"Lamba","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.2741\/3563","article-title":"Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio.","volume":"14","author":"Modica","year":"2009","journal-title":"Front Biosci"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jbt.20180","article-title":"Mechanisms of cytochrome P450 induction.","volume":"21","author":"Tompkins","year":"2007","journal-title":"J Biochem Mol Toxicol"},{"key":"R19-8-20210129","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1074\/jbc.274.10.6043","article-title":". The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene.","volume":"274","author":"Sueyoshi","year":"1999","journal-title":"J Biol Chem"},{"key":"R20-8-20210129","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1086\/592304","article-title":". Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C--T) with reduced concentrations of unboosted atazanavir.","volume":"47","author":"Siccardi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R21-8-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/dmd.31.1.7","article-title":"Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels.","volume":"31","author":"Chang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R22-8-20210129","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/135965350400900510","article-title":". Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.","volume":"9","author":"Owen","year":"2004","journal-title":"Antivir Ther"},{"key":"R23-8-20210129","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1124\/dmd.107.019380","article-title":". ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: implications in hepatic stress responses.","volume":"36","author":"Pascual","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R24-8-20210129","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/dmd.31.6.755","article-title":". Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.","volume":"31","author":"Westlind-Johnsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R25-8-20210129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2005.05.011","article-title":". Functional analysis of four naturally occurring variants of human constitutive androstane receptor.","volume":"86","author":"Ikeda","year":"2005","journal-title":"Mol Genet Metab"},{"key":"R26-8-20210129","first-page":"4","article-title":". Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents.","volume":"3","author":"la Porte","year":"2006","journal-title":"Rev Antiviral Ther"},{"key":"R27-8-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":". Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R28-8-20210129","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":". Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"R29-8-20210129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2007.02884.x","article-title":"CYP2B6 983TC polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIVAIDS treatment.","volume":"64","author":"Mehlotra","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R30-8-20210129","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":". Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.","volume":"66","author":"Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R31-8-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":". Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R32-8-20210129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/09540120410001716342","article-title":". Factors associated with efavirenz discontinuation in a large community-based sample of patients.","volume":"16","author":"Spire","year":"2004","journal-title":"AIDS Care"},{"key":"R33-8-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/605126","article-title":". CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.","volume":"200","author":"Leger","year":"2009","journal-title":"J Infect Dis"},{"key":"R34-8-20210129","first-page":"111","article-title":"CAR and PXR: xenosensors of endocrine disrupters Chem Biol Interact.","volume":"155","author":"Kretschmer","year":"2005","journal-title":""},{"key":"R35-8-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/03602530600786232","article-title":". PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity.","volume":"38","author":"Stanley","year":"2006","journal-title":"Drug Metab Rev"},{"key":"R36-8-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002040050588","article-title":". Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.","volume":"73","author":"Yamazaki","year":"1999","journal-title":"Arch Toxicol"},{"key":"R37-8-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.taap.2003.12.027","article-title":". PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators.","volume":"199","author":"Lamba","year":"2004","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318274197e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:30:29Z","timestamp":1745224229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201302000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318274197e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}